Nectar Lifesciences Ltd (NECLIFE) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532649 | NSE: NECLIFE | Pharmaceuticals & Drugs | Small Cap

Nectar Lifesciences Share Price

20.95 0.01 0.05%
as on 05-Dec'25 16:59

Nectar Lifesciences Ltd (NECLIFE) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532649 | NSE: NECLIFE | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Nectar Lifesciences

Based on:

Overall Rating
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Nectar Lifesciences stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
469.8 Cr.
52-wk low:
13.3
52-wk high:
44.9

Is Nectar Lifesciences Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Nectar Lifesciences: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Nectar Lifesciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 10%9.7%9.1%10.3%8.2%1.4%5.8%2.6%6.7%-4.7%-
Value Creation
Index
-0.3-0.3-0.4-0.3-0.4-0.9-0.6-0.8-0.5-1.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,6761,6431,8762,7852,3631,5421,6681,5241,6841,6701,169
Sales YoY Gr.--2%14.1%48.5%-15.2%-34.8%8.2%-8.7%10.5%-0.8%-
Adj EPS 2.42.42.32.11.3-2.50.8-2.6-0.1-5.3-8.3
YoY Gr.--0.4%-3.7%-9%-37.3%-285.7%NA-406%NANA-
BVPS (₹) 42.644.947.249.350.647.348.547.547.742.632
Adj Net
Profit
54.454.352.247.529.9-55.418.7-57.7-2-120-186
Cash Flow from Ops. 16919965.123928621.395133225169-
Debt/CF from Ops. 5.74.414.73.82.742.49.15.72.83.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -0%-6.7%0%-0.8%
Adj EPS -209.1%-232.1%-285.3%NA
BVPS0%-3.4%-4.2%-10.6%
Share Price -9.6% 1% -3.4% -36.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
5.75.55.14.42.7-51.7-5.4-0.2-11.8-22.2
Op. Profit
Mgn %
14.313.612.69.59.26.69.53.69-1.8-14.7
Net Profit
Mgn %
3.33.32.81.71.3-3.61.1-3.8-0.1-7.2-15.9
Debt to
Equity
10.90.90.80.70.90.80.70.60.60
Working Cap
Days
2983242922062403302883102722621,231
Cash Conv.
Cycle
142153133104115132108126109111-2,032

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Nectar Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) -8.3 -16.1
TTM Sales (₹ Cr.) 1,169 1,169
BVPS (₹.) 32 32
Reserves (₹ Cr.) 694 694
P/BV 0.66 0.66
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 13.25 / 44.90
All Time Low / High (₹) 7.20 / 60.90
Market Cap (₹ Cr.) 470
Equity (₹ Cr.) 22.4
Face Value (₹) 1
Industry PE 40.6

Management X-Ray of Nectar Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *100.00100.00100.00100.00100.00100.0099.6099.6099.6098.77
* Pledged shares as % of Promoter's holding (%)

Valuation of Nectar Lifesciences - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Nectar Lifesciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales1,6761,6431,8762,7852,3631,5421,6681,5241,6841,670
Operating Expenses 1,4371,4191,6392,5212,1451,4401,5091,4691,5331,700
Manufacturing Costs127129145154140129147173186164
Material Costs1,1751,1541,3662,2211,8581,1561,2221,1591,2021,368
Employee Cost 78767577787172758294
Other Costs 57615469698568626374
Operating Profit 23922423626421810215955152-30
Operating Profit Margin (%) 14.2%13.6%12.6%9.5%9.2%6.6%9.5%3.6%9.0%-1.8%
Other Income 6236641111532716
Interest 12311711514812611279899986
Depreciation 57626463616057596162
Exceptional Items 00000-250000
Profit Before Tax 6467635936-8534-4118-162
Tax 101210116-129-1813-48
Profit After Tax 5455524730-7325-225-114
PAT Margin (%) 3.2%3.4%2.8%1.7%1.3%-4.7%1.5%-1.5%0.3%-6.8%
Adjusted EPS (₹)2.42.52.32.11.3-3.31.1-1.00.2-5.1
Dividend Payout Ratio (%)4%2%2%2%4%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 9541,0071,0591,1051,1351,0611,0871,0651,069956
Share Capital 22222222222222222222
Reserves 9329841,0361,0821,1121,0381,0641,0421,047934
Minority Interest0000000000
Debt873794854802741840794685553500
Long Term Debt24516422016612112829122614060
Short Term Debt627630634636620712503459412440
Trade Payables497528539483527342377319420438
Others Liabilities 23325227231522913213010014298
Total Liabilities 2,5572,5812,7242,7042,6322,3752,3872,1692,1841,992

Fixed Assets

Gross Block1,3841,3641,4561,4901,5091,5561,5631,5581,5991,652
Accumulated Depreciation4784826046667247848408969571,019
Net Fixed Assets 906881852825785772723662643633
CWIP 991021001001159985786657
Investments 1111111111
Inventories836854859915975587660673709690
Trade Receivables492500612561397375447280379345
Cash Equivalents 3613921212518182019
Others Assets 186229290282338516454459366247
Total Assets 2,5572,5812,7242,7042,6322,3752,3872,1692,1841,992

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 169199652392862195133225169
PBT 6567635936-8534-4118-162
Adjustment 17415917620718814812597138139
Changes in Working Capital -62-20-161-1372-39-657769192
Tax Paid -9-7-13-14-9-40000
Cash Flow From Investing Activity -77-18-29-26-33-291752-17-42
Capex -82-25-33-36-36-311550-29-44
Net Investments -10-000-00100
Others 673103322122
Cash Flow From Financing Activity -89-204-40-201-25211-119-186-205-128
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 5-8773-53-10832166-62-72-82
Interest Paid -123-117-115-148-126-112-79-79-87-75
Dividend Paid -3-3-1-1-1-10000
Others 32342-1692-206-44-4728
Net Cash Flow 3-24-41214-8-02-1

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)5.795.625.054.382.68-6.662.36-2.090.47-11.23
ROCE (%)9.959.719.1210.288.241.415.792.586.68-4.68
Asset Turnover Ratio0.710.680.791.150.990.70.810.770.880.91
PAT to CFO Conversion(x)3.133.621.255.099.53N/A3.8N/A45N/A
Working Capital Days
Receivable Days961049769668078766269
Inventory Days166177149104131162118139131134
Payable Days1481621438499137107109112114

Nectar Lifesciences Ltd Stock News

Nectar Lifesciences Ltd FAQs

The current trading price of Nectar Lifesciences on 05-Dec-2025 16:59 is ₹20.95.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Nectar Lifesciences stood at ₹469.8.
The latest P/E ratio of Nectar Lifesciences as of 04-Dec-2025 is 0.00.
The latest P/B ratio of Nectar Lifesciences as of 04-Dec-2025 is 0.66.
The 52-week high of Nectar Lifesciences is ₹44.90 and the 52-week low is ₹13.25.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nectar Lifesciences is ₹1,169 ( Cr.) .

About Nectar Lifesciences Ltd

Nectar Lifesciences Ltd. (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. It has emerged as top ranked organization amongst midsized Pharmaceutical companies in India as per “Fortune Next 500” 2017 & is  among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per “Bio-Spectrum Asia Pacific” 2016 besides being one of the top amongst Indian API manufacturers.

The company has transformed itself from being a small Domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. It currently has a strong hold of API & Formulation business in many countries of the world with various State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels.

Business area of the company

The company has developed fully integrated sustainable production systems to manufacture high quality Cephalosporin intermediates, - Active Pharmaceuticals ingredients (APIs) and Finished Dosage Formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and over many countries worldwide.

Business segments

  • APIs
  • Formulations
  • Empty hard Gelatin Capsules
  • Phytochemicals

Certifications

  • GMP (Issued by World Health Organization - COPP)
  • ISO 9001:2008 - Quality Management
  • ISO 22000:2005 - Food Safety Management
  • ISO 14001: 2004 - Environment Management Systems
  • ISO 50001: 2011 - Energy Management System
  • OHSAS 18001: 2007 - Occupational Health and Safety
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×